As Federal Agencies Now Look to Meet the Executive Order's Ambitious Timelines, EASEL-AI Offers an Immediately Available Tool That Reduces Manual Review Workloads and Accelerates Time to Decision for Complex UAS Operations
Read More
HIMSS25 Europe takes place June 10-12, 2025 at the Palais des Congrès in Paris, showcasing the latest digital health innovations and driving collaboration across the European healthcare IT ecosystem.
Read More
A culture change is affecting how people talk about cosmetic surgery, from popular TikToks to BBL reversals. Dr. Meegan Gruber shows why choices made with knowledge and power are becoming more critical.
Read MoreMichael Howe - who currently serves as an Independent Board Member - to assume CEO role on June 10, 2025
Michael's career spans nationally recognized brands such as MinuteClinic, Procter & Gamble, PepsiCo, CEO of Arby's, and as an early-stage investor/board member in healthcare and software businesses
Read MoreNew software integration is among the first multi-unit operators to roll out AI note integration directly into the Company's medical software
Read MoreShortDot Registry, a global leader in domain innovation, is pleased to announce a new strategic collaboration with the .buzz registry to operate and grow the .buzz domain extension as part of ShortDot’s Registry Services Program.
Read More
DEA Back to Training School, DEA Bureaucrat Blocks Science While Ignoring their Own TRAINING Manual.
DEA Assistant Administrators and attorney needs a summer assignment, and MMJ BioPharma Cultivation has a suggestion: go back and read your own policy statement and training manual.
Read More
Early surface reconnaissance and drilling progress sharpen silver focus
HIGHLIGHTS
Current ~2,500m reverse circulation (RC) drilling program underway at Tolmer discovery; planned gold drilling reallocated to prioritise silver zone following early observations1
Additional target holes added north, east, south and west of high-grade ‘discovery line'2
Gross proceeds from offering total $16.6 million.
Financing led by long-term, healthcare-focused institutional investors, including Aytu's largest shareholders Nantahala Capital Management and Stonepine Capital Management, with participation from Aytu management and new institutional shareholders.
Aytu enters the over $22 billion United States prescription major depressive disorder ("MDD") market with the first-in-class oral selective serotonin 5HT1a receptor agonist for adults with MDD.
EXXUA has demonstrated significant improvement in depression symptoms in clinical trials involving more than 5,000 patients and, notably, the incidence of sexual side effects experienced with EXXUA was comparable to placebo.
EXXUA is expected to serve as a major growth catalyst as Aytu continues to build value for shareholders; the Company anticipates launching EXXUA in the fourth calendar quarter of 2025 as a centerpiece of its commercial efforts.
Conference call to discuss the EXXUA opportunity and commercialization plan scheduled for Wednesday, June 11, 2025, at 4:30 p.m. Eastern time.
Read MoreZherka: ‘My Banks Got Paid, My Rights Got Taken' - Government Overreach Mirrors Trump's Political Witch Hunt
Real estate titan vows Supreme Court appeal after court upholds lifetime gun ban for nonviolent conviction: “This is lawfare, plain and simple.”
Read MoreClick here to register
Discussion will focus on company's May 2025 meeting with the FDA to review the statistically significant responder analysis results for the subgroup of breast cancer patients in company's recently conducted Phase 3 OnTarget trial
The currently estimated US metastatic breast cancer population potentially qualifies as an orphan population, in alignment with company's core focus on orphan diseases
Company plans to promptly pursue authorization to initiate expanded access program for patients with breast cancer who may not be eligible for a potential pivotal treatment trial with crofelemer in patients with metastatic breast cancer
Read More
Angel Ai CEO and fintech visionary Pavan Agarwal attended Bitcoin 2025, the largest Bitcoin event of the year, held in Las Vegas. The conference was a landmark moment in the evolving convergence of AI, blockchain, and digital currency, drawing high-profile speakers and innovators across industries-from government leaders like Vice president JD Vance, Eric Trump, Donald Trump Jr., NYC Mayor Eric Adams, and Bo Hines, the U.S. Head of Cryptocurrency, to real estate mogul Josh Altman, and high profile technology leaders like David Sacks, Michael Saylor, and Michael Terpin.
Read More
Productive and collaborative discussion on proposed pathway by the company to bring crofelemer to approval for cancer therapy-related diarrhea (CTD) in patients with metastatic breast cancer receiving selected targeted therapies
The currently estimated US metastatic breast cancer population would qualify as an orphan population, which aligns with company's core focus on orphan diseases
Company plans to promptly pursue authorization to initiate expanded access program for patients with breast cancer who may not be eligible for a potential pivotal treatment trial with crofelemer in patients with metastatic breast cancer
Read More
